RGS12

Regulator of G-protein signaling 12 · O14924 · RGS12 on Sugi Atlas →

33,657 patent compounds predicted against RGS12, 25,117 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Tyrphostin A9 (SCHEMBL120440)	1.00	4/20
SCHEMBL21124	1.00	3/20
Tyrphostin 25 (SCHEMBL239879)	1.00	3/20
Mesulergine (SCHEMBL292175)	0.66	3/20
Tyrphostin 23 (SCHEMBL241922)	0.64	3/20
Tyrphostin 51 (SCHEMBL241622)	0.55	3/20
SCHEMBL272248	0.47	3/20
SCHEMBL544054	0.44	3/20
Methysergide (SCHEMBL41843)	1.00	2/20
SCHEMBL107293	1.00	2/20
Metergoline (SCHEMBL117882)	1.00	2/20
Sanguinarium (SCHEMBL123241)	1.00	2/20
SCHEMBL140170	1.00	2/20
R-N-Propylnorapomorphine (SCHEMBL249729)	1.00	2/20
Methysergide (SCHEMBL467883)	1.00	2/20
Methysergide (SCHEMBL467884)	1.00	2/20
Sanguinarium (SCHEMBL43290)	0.97	2/20
Sanguinarium (SCHEMBL454298)	0.91	2/20
Methysergide (SCHEMBL41844)	0.90	2/20
SCHEMBL242896	0.71	2/20

Clinical trials — most relevant to RGS12 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Investigating the Potential Role of Aerosolized Retinoic Acid, a Potent Vitamin A Metabolite for Treating COVID-19 Anosmia and Retinoic Acid Insufficiency .A Novel Approach for Regaining Sense of Smell.	PHASE4	UNKNOWN
The Therapeutic Effect of Bromocriptin in Patients With Primary Aldosteronism	PHASE4	UNKNOWN
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old	PHASE2	ACTIVE_NOT_RECRUITING
Paroxetine-mediated GRK2 Inhibition to Reduce Cardiac Remodeling After Acute Myocardial Infarction	PHASE2	COMPLETED
Pentoxifylline as an Adjunctive in Treatment of Negative Symptoms in Chronic Schizophrenia	PHASE1/PHASE2	COMPLETED
Intravenous Allopurinol to Improve Heart Function in Individuals With Dilated Cardiomyopathy	PHASE1/PHASE2	WITHDRAWN
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients	PHASE1/PHASE2	WITHDRAWN
Antidepressant Effects on cAMP Specific Phosphodiesterase (PDE4) in Depressed Patients	PHASE1	COMPLETED
Intravenous Terbutaline in Severe Status Asthmaticus	nan	UNKNOWN
Thrombin Regulated Platelet Activation	nan	COMPLETED
Adrenocorticotropic Hormone (ACTH) Stimulation and G Protein	nan	COMPLETED
Brain Receptors in Sympathetic Nervous System Regulation	nan	COMPLETED
Acute Asthma Responsiveness and B2 Adrenergic Receptors Polymorphisms	nan	COMPLETED
Assessment of CXCL5 Level in SLE Patients and Its Correlation with Disease Activity	nan	NOT_YET_RECRUITING
A Role for RAGE/TXNIP/Inflammasome Axis in Alveolar Macrophage Activation During ARDS (RIAMA): a Proof-of-concept Clinical Study	nan	COMPLETED
Pilot Study Evaluating Neuro-Imaging Correlates of Epigenetic Finding in Prediction of Chronic Postsurgical Pain	nan	UNKNOWN
Brain Tissue Integrity and Autonomic Function Alterations in Childhood OSA and ADHD, and After Adenotonsillectomy.	nan	UNKNOWN
Defining the Brain Phenotype of Children With Williams Syndrome	nan	RECRUITING
Integrins and Protocadherins in Glutamatergic Circuits: Identification of Common Signaling Pathways and Molecular Targets in Anxiety and Major Depressive Disorders (GAPsy)	nan	UNKNOWN
Effect of Intraperitoneal Bupivacaine with Dexmedotomidine or Fentanyl for Post-Operative Analgesia Following Laparoscopy in Pediatric Patients	nan	NOT_YET_RECRUITING
Development of Therapeutic Approaches Modulating Molecular Targets Implicated on Cancer Stem Cell-related Aggressiveness	nan	UNKNOWN
The Application of 68Ga-Pentixafor Alongside 68Ga-FAPI-04 PET/MR for Assessing Primary Aldosteronism.	nan	NOT_YET_RECRUITING
Glycine and Magnesium+Thiamine for the Treatment of Primary Ciliary Dyskinesia	nan	RECRUITING
Effects of Antidepressant on Postsynaptic Signal Transduction in Serotonergic System of Depressed Patients	nan	UNKNOWN
Pattern of Gene Expression in Adipose Tissue From Patients With Cushing Syndrome	nan	COMPLETED
Effect of Mechanical Ventilation on Plasma Concentration Level of R-spondin Proteins	nan	COMPLETED
Transcriptomic Profile of Patients Treated With Different Modalities of Spinal Cord Stimulation	nan	UNKNOWN
Role of MicroRNAs on Age and Contraction-induced Skeletal Muscle Growth	nan	COMPLETED
Glycosylation in Patients With Galactosaemia	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a RGS12 binder may also engage these)

Protein	Name	Similarity
O08774	—	1.000	O08774 →
Q8CGE9	—	1.000	Q8CGE9 →
Q60610	—	0.999	Q60610 →
Q8R0S2	—	0.998	Q8R0S2 →
Q6DN90	—	0.997	Q6DN90 →
A0A0G2JUG7	—	0.996	A0A0G2JUG7 →
Q6P1I6	—	0.996	Q6P1I6 →
MAP3K9	Mitogen-activated protein kinase kinase kinase 9	0.995	landscape →
E9Q9W7	—	0.994	E9Q9W7 →
Q9D3S3	—	0.994	Q9D3S3 →
Q5RJW5	—	0.993	Q5RJW5 →
Q9D684	—	0.993	Q9D684 →
Q8C0T5	—	0.993	Q8C0T5 →
Q2PFD7	—	0.993	Q2PFD7 →
G3X9J0	—	0.993	G3X9J0 →
Q76G19	—	0.993	Q76G19 →
Q9H329	—	0.993	Q9H329 →
Q6NN85	—	0.993	Q6NN85 →
Q8C115	—	0.993	Q8C115 →
Q5SSZ5	—	0.993	Q5SSZ5 →
O70405	—	0.993	O70405 →
TIAM1	Rho guanine nucleotide exchange factor TIAM1	0.993	landscape →
A5D794	—	0.993	A5D794 →
Q6DFC8	—	0.993	Q6DFC8 →
Q1LYM3	—	0.993	Q1LYM3 →
A0M8T5	—	0.992	A0M8T5 →
Q5T9C2	—	0.992	Q5T9C2 →
Q64512	—	0.992	Q64512 →
P57095	—	0.992	P57095 →
Q2NKQ1	—	0.992	Q2NKQ1 →